Determination of Blood Tumor Cells

A Clinical Research of CD20-Targeted CAR-T in B Cell Malignancies

NCT02710149 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2

CD 70 CAR T for Patients With CD70 Positive Malignant Hematologic Diseases

NCT04662294 ·Status: RECRUITING ·Phase: EARLY_PHASE1

CD19/20 Bispecific Nanobody-derived CAR-T Cells in B Cell Lymphoma

NCT03881761 ·Status: UNKNOWN ·Phase: PHASE1

CAR-T Cells Combined With Peptide Specific Dendritic Cell in Relapsed/Refractory Leukemia/MDS

NCT03291444 ·Status: RECRUITING ·Phase: PHASE1

Combination Transfer of αCD19-TCRz-41BB and αCD22-TCRz-41BB CAR-T Cells for B-cell Hematologic Malignancy

NCT02903810 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2

Tissue Study in Patients Undergoing CAR-T Cell Therapy (CAR_21_01)

NCT04892433 ·Status: RECRUITING

A Clinical Study to Explore CT1194D in Patients With Relapsed/Refractory B-Cell Neoplasms

NCT07200479 ·Status: NOT_YET_RECRUITING ·Phase: PHASE1

Cord Blood Derived CAR-T Cells in Refractory/Relapsed B Cell Malignancies

NCT03881774 ·Status: UNKNOWN ·Phase: PHASE1

Anti-CD30 CAR-T Therapy in Patients With Refractory/Relapsed Lymphocyte Malignancies

NCT04008394 ·Status: UNKNOWN ·Phase: PHASE1

Treatment of Relapsed and/or Chemotherapy Refractory Advanced Malignancies by CART133

NCT02541370 ·Status: COMPLETED ·Phase: PHASE1/PHASE2

Clinical Study of CAR-iNKT Cells in the Treatment of Relapsed/Refractory/High-risk B-cell Tumors

NCT04814004 ·Status: UNKNOWN ·Phase: PHASE1

CAR-T Technology for Recurrent/Refractory Malignant Hematological and Lymphatic Tumors

NCT06647329 ·Status: NOT_YET_RECRUITING ·Phase: PHASE1

A Study of CAR-T Cells Therapy for Patients With Relapsed and/or Refractory Central Nervous System Hematological Malignancies

NCT04532203 ·Status: RECRUITING ·Phase: EARLY_PHASE1

A Study of LY2510924 and Durvalumab in Participants With Solid Tumors

NCT02737072 ·Status: TERMINATED ·Phase: PHASE1

Precise Design of Cell Therapy for Relapsed and Refractory Hematological Tumors

NCT06849921 ·Status: ACTIVE_NOT_RECRUITING ·Phase: NA

Clinical Study of ET019002-T Cell Therapy for Refractory/Relapsed B-Cell Malignancies

NCT03642496 ·Status: UNKNOWN ·Phase: EARLY_PHASE1

Clinical Study of Novel TLR2-Containing CAR-T Cells Targeting CD19 and CD22 for Relapsed/Refractory B-ALL and NHL

NCT06879262 ·Status: NOT_YET_RECRUITING ·Phase: EARLY_PHASE1

WT1 Immunity Via DNA Fusion Gene Vaccination in Haematological Malignancies by Intramuscular Injection Followed by Intramuscular Electroporation

NCT01334060 ·Status: COMPLETED ·Phase: PHASE2

A Clinical Research of CD33-Targeted CAR-T in Myeloid Malignancies

NCT02958397 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2

CD79b CAR-T Cell Therapy for Patients With Relapsed and/or Refractory Acute Lymphoblastic Leukemia and B-cell Non-Hodgkin's Lymphoma

NCT04609241 ·Status: NOT_YET_RECRUITING ·Phase: EARLY_PHASE1

Predictive Factors for the Efficacy of CD19 CAR-T Therapy in Relapsed/Refractory Large B-Cell Lymphoma: A Clinical Study

NCT07236203 ·Status: RECRUITING

A Study Evaluating the Safety, Tolerability and Preliminary Efficacy of IBI322 in Subjects With Hematologic Malignancy

NCT04795128 ·Status: COMPLETED ·Phase: PHASE1

Treatment of Hematological Malignancy With Novel CAR-T Cells.

NCT04191941 ·Status: UNKNOWN ·Phase: EARLY_PHASE1

CAR-T Cell Efficacy With Molecular Imaging in Multiple Myeloma

NCT07280793 ·Status: NOT_YET_RECRUITING ·Phase: EARLY_PHASE1

Targeting CD19 and CD22 CAR-T Cells Immunotherapy in Patients With Relapsed or Refractory Acute B Lymphocytic Leukemia

NCT04714593 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2